
Kezar Life Sciences, Inc. (NASDAQ:KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).
The MISSION Phase 2 clinical trial study is designed to demonstrate the responder rate of zetomipzomib in patients with active lupus nephritis (LN).